JP MORGAN/CALL/BOSTON SCIENTIFIC/74/0.1/16.08.24 Share Price

Warrant

DE000JK3AZR1

Real-time Bid/Ask 07:38:24 02/07/2024 pm IST
0.48 EUR / 0.49 EUR -13.39% Intraday chart for JP MORGAN/CALL/BOSTON SCIENTIFIC/74/0.1/16.08.24
Current month-1.75%
1 month+1.82%
Date Price Change
02/24/02 0.5 -10.71%
01/24/01 0.56 -1.75%
28/24/28 0.57 -1.72%
27/24/27 0.58 +1.75%
25/24/25 0.57 -9.52%

Delayed Quote Börse Stuttgart

Last update July 02, 2024 at 01:36 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying BOSTON SCIENTIFIC CORPORATION
Issuer J.P. Morgan
WKN JK3AZR
ISINDE000JK3AZR1
Date issued 16/02/2024
Strike 74 $
Maturity 16/08/2024 (45 Days)
Parity 10 : 1
Emission price 0.17
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.68
Lowest since issue 0.32
Delta0.63x
Omega 9.044
Premium4.18x
Gearing14.34x
Moneyness 1.029
Difference Strike -1.99 $
Difference Strike %-2.69%
Spread 0.01
Spread %2.00%
Theoretical value 0.4950
Implied Volatility 36.89 %
Total Loss Probability 41.89 %
Intrinsic value 0.1986
Present value 0.2964
Break even 79.31 €
Theta-0.03x
Vega0.01x
Rho0x

Company Profile

Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows: - cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%); - endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ; - neuromodulation (2%). The United States account for 59.2% of net sales.
Sector
-
More about the company

Ratings for Boston Scientific Corporation

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Boston Scientific Corporation

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
76.41 USD
Average target price
82.35 USD
Spread / Average Target
+7.78%
Consensus